Ricky obtained his PhD in cancer genomics from the University of Leicester, before joining the University of Cambridge as a postdoc. His postdoctoral work focused on identification of mechanisms of resistance to anti-cancer compounds in paediatric malignancies. In this project, he employed genome-wide CRISPR knockout and activation screens to identify novel drug targets and devised novel combination treatment strategies to prevent emergence of drug resistance in mouse cancer models. Ricky recently joined the Functional Genomics team at GSK and is conducting genome-wide CRISPR knockout screens in primary immune cells for target identification. He is also developing tools to enable CRISPR activation studies in primary cells.